{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:42:39Z","timestamp":1792698159281,"version":"4.5.0"},"reference-count":55,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172704"],"award-info":[{"award-number":["82172704"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473298"],"award-info":[{"award-number":["82473298"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Top-level Talents Project of Health Commission of Henan Province, China","award":["YXKC2022014"],"award-info":[{"award-number":["YXKC2022014"]}]},{"name":"Beijing Bethune Foundation","award":["2024-YJ-154-S-014"],"award-info":[{"award-number":["2024-YJ-154-S-014"]}]},{"name":"Henan Provincial Department of Education Project","award":["27A320039"],"award-info":[{"award-number":["27A320039"]}]},{"name":"Medical Science and Technology Key Project of Henan Province, China","award":["LHGJ20260363"],"award-info":[{"award-number":["LHGJ20260363"]}]},{"name":"Medical Science and Technology Key Project of Henan Province, China","award":["SBGJ202302038"],"award-info":[{"award-number":["SBGJ202302038"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,10,10]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/jitc-2026-015492","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:05:17Z","timestamp":1792695917000},"page":"e015492","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Development and preclinical evaluation of tetraspecific antibodies in combination with ex vivo expanded NK cells infusion for improved control of esophageal cancer"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9204-6548","authenticated-orcid":false,"given":"Yafei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Advanced Medical Research Center for Prevention and Treatment of Thoracic Disease, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Henan Molecular Pathology and Clinical Experimental Engineering Research Center of Thoracic Disease, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyang","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Henan Molecular Pathology and Clinical Experimental Engineering Research Center of Thoracic Disease, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Henan Molecular Pathology and Clinical Experimental Engineering Research Center of Thoracic Disease, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Advanced Medical Research Center for Prevention and Treatment of Thoracic Disease, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinliang","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Advanced Medical Research Center for Prevention and Treatment of Thoracic Disease, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[{"name":"Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Advanced Medical Research Center for Prevention and Treatment of Thoracic Disease, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Henan Molecular Pathology and Clinical Experimental Engineering Research Center of Thoracic Disease, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"2026102212050919000_14.10.e015492.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026102212050919000_14.10.e015492.2","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1053\/j.gastro.2025.12.019","article-title":"Targeting APE1-Redox Function Reverses SOX9-mediated Chemoresistance in Esophageal Adenocarcinoma","volume":"170","author":"Lu","year":"2026","journal-title":"Gastroenterology"},{"key":"2026102212050919000_14.10.e015492.3","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12645"},{"key":"2026102212050919000_14.10.e015492.4","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1109\/TMI.2026.3670159","article-title":"Preoperative Prediction of Esophageal Cancer Survival in CT via Tumor and Lymph Node Context and Geometry Modeling","volume":"45","author":"Gong","year":"2026","journal-title":"IEEE Trans Med Imaging"},{"key":"2026102212050919000_14.10.e015492.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.10.002"},{"key":"2026102212050919000_14.10.e015492.6","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7076","article-title":"Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis","volume":"13","author":"Gaber","year":"2024","journal-title":"Cancer Med"},{"key":"2026102212050919000_14.10.e015492.7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13046-025-03514-4","article-title":"The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy","volume":"44","author":"Hussein","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"2026102212050919000_14.10.e015492.8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s43018-025-00918-1","article-title":"Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802)","volume":"6","author":"Bando","year":"2025","journal-title":"Nat Cancer"},{"key":"2026102212050919000_14.10.e015492.9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026102212050919000_14.10.e015492.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380"},{"key":"2026102212050919000_14.10.e015492.11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s43018-025-00955-w","article-title":"Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma","volume":"6","author":"Barroux","year":"2025","journal-title":"Nat Cancer"},{"key":"2026102212050919000_14.10.e015492.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53164-x","article-title":"The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma","volume":"15","author":"Jiang","year":"2024","journal-title":"Nat Commun"},{"key":"2026102212050919000_14.10.e015492.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20019-0"},{"key":"2026102212050919000_14.10.e015492.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06945-1"},{"key":"2026102212050919000_14.10.e015492.15","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase\u20091 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat Med"},{"key":"2026102212050919000_14.10.e015492.16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-023-02918-4","article-title":"NK cell-triggered CCL5\/IFN\u03b3-CXCL9\/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer","volume":"43","author":"Santana-Hern\u00e1ndez","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"2026102212050919000_14.10.e015492.17","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70387","article-title":"Natural Killer Cell-Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications","volume":"6","author":"Luo","year":"2025","journal-title":"MedComm (2020)"},{"key":"2026102212050919000_14.10.e015492.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03792-7"},{"key":"2026102212050919000_14.10.e015492.19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-24-1991","article-title":"First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors","volume":"31","author":"El-Khoueiry","year":"2025","journal-title":"Clinical Cancer Research"},{"key":"2026102212050919000_14.10.e015492.20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40259-025-00712-6","article-title":"Multispecific Antibodies Targeting PD-1\/PD-L1 in Cancer","volume":"39","author":"Chen","year":"2025","journal-title":"BioDrugs"},{"key":"2026102212050919000_14.10.e015492.21","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70046","article-title":"Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy","volume":"14","author":"Zhu","year":"2024","journal-title":"Clin Transl Med"},{"key":"2026102212050919000_14.10.e015492.22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7095","article-title":"A phase 1\/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and\/or refractory CD20-expressing non-Hodgkin lymphoma","volume":"42","author":"Falchi","year":"2024","journal-title":"JCO"},{"key":"2026102212050919000_14.10.e015492.23","unstructured":"Liu Y , Fan X , Zuo X , et al . Data from: development and preclinical evaluation of tetraspecific antibodies in combination with ex vivo expanded nk cells infusion for improved control of esophageal cancer. Gene Expression Omnibus (GEO); 2026. Available: https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE341700"},{"key":"2026102212050919000_14.10.e015492.24","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1158\/0008-5472.CAN-22-2593","article-title":"Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma","volume":"83","author":"Wu","year":"2023","journal-title":"Cancer Res"},{"key":"2026102212050919000_14.10.e015492.25","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200898R","article-title":"Profiling transcriptional heterogeneity of epithelium, fibroblasts, and immune cells in esophageal squamous cell carcinoma by single-cell RNA sequencing","volume":"36","author":"Shi","year":"2022","journal-title":"FASEB J"},{"key":"2026102212050919000_14.10.e015492.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105854","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study","volume":"10","author":"Metges","year":"2025","journal-title":"ESMO Open"},{"key":"2026102212050919000_14.10.e015492.27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cac2.12645","article-title":"Current status and perspectives of esophageal cancer: a comprehensive review","volume":"45","author":"Jiang","year":"2025","journal-title":"Cancer Commun"},{"key":"2026102212050919000_14.10.e015492.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.09.013"},{"key":"2026102212050919000_14.10.e015492.29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41423-025-01297-4","article-title":"Adjusting the scope of natural killer cells in cancer therapy","volume":"22","author":"Shen","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"2026102212050919000_14.10.e015492.30","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1016\/j.ymthe.2025.09.003","article-title":"Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections","volume":"33","author":"Velasco-de-Andr\u00e9s","year":"2025","journal-title":"Mol Ther"},{"key":"2026102212050919000_14.10.e015492.31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026102212050919000_14.10.e015492.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104912","article-title":"Beyond CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy","volume":"214","author":"Zhang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026102212050919000_14.10.e015492.33","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-25-0820","article-title":"ABBV-303 Is an NK-cell Engager Specific for c-Met-Expressing Tumors","volume":"86","author":"Stone","year":"2026","journal-title":"Cancer Res"},{"key":"2026102212050919000_14.10.e015492.34","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-2354","article-title":"Ex vivo expanded adaptive NK cells in combination with a bispecific NK cell engager targeting BCMA for synergistic control of multiple myeloma","volume":"146","author":"Boxaspen","year":"2025","journal-title":"Blood"},{"key":"2026102212050919000_14.10.e015492.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02524-0","article-title":"Anti-MSLN chimeric antigen receptor-like NK cell therapy with tumor-penetrating capacity (uCAR-like NK) for solid tumors","volume":"10","author":"An","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026102212050919000_14.10.e015492.36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu0690","article-title":"Discovery and preclinical evaluation of monoclonal antibodies and bispecific engagers targeting the NKG2A inhibitory receptor","volume":"12","author":"Shin","year":"2026","journal-title":"Sci Adv"},{"key":"2026102212050919000_14.10.e015492.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011370","article-title":"Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer","volume":"13","author":"Khaw","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026102212050919000_14.10.e015492.38","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.45"},{"key":"2026102212050919000_14.10.e015492.39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1208"},{"key":"2026102212050919000_14.10.e015492.40","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x2020e10877","article-title":"MET overexpression and intratumor heterogeneity in esophageal squamous cell carcinoma","volume":"54","author":"Abboud","year":"2021","journal-title":"Braz J Med Biol Res"},{"key":"2026102212050919000_14.10.e015492.41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11060-016-2251-5","article-title":"Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma","volume":"130","author":"Tabouret","year":"2016","journal-title":"J Neurooncol"},{"key":"2026102212050919000_14.10.e015492.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-015-0633-7","article-title":"Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer","volume":"13","author":"Madoz-G\u00farpide","year":"2015","journal-title":"J Transl Med"},{"key":"2026102212050919000_14.10.e015492.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01659-y"},{"key":"2026102212050919000_14.10.e015492.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.01.004"},{"key":"2026102212050919000_14.10.e015492.45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1624751","article-title":"Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer","volume":"16","author":"Stefa\u0144czyk","year":"2025","journal-title":"Front Immunol"},{"key":"2026102212050919000_14.10.e015492.46","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202519574","article-title":"PD\u2010L1\u2010Binding Antigen Presenters: Redirecting Vaccine\u2010Induced Antibodies for Cancer Immunotherapy","volume":"13","author":"Gao","year":"2026","journal-title":"Advanced Science"},{"key":"2026102212050919000_14.10.e015492.47","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1021\/acs.molpharmaceut.1c00208","article-title":"Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC","volume":"18","author":"van Faassen","year":"2021","journal-title":"Mol Pharm"},{"key":"2026102212050919000_14.10.e015492.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.04.041"},{"key":"2026102212050919000_14.10.e015492.49","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2022.100783","article-title":"Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant","volume":"3","author":"Demaria","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026102212050919000_14.10.e015492.50","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adp3720","article-title":"A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma","volume":"9","author":"Demaria","year":"2024","journal-title":"Sci Immunol"},{"key":"2026102212050919000_14.10.e015492.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104691","article-title":"Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy","volume":"155","author":"Wu","year":"2020","journal-title":"Pharmacol Res"},{"key":"2026102212050919000_14.10.e015492.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00808-3"},{"key":"2026102212050919000_14.10.e015492.53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.13611","article-title":"NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-\u03b3\/p-STAT1\/IRF1 pathway","volume":"169","author":"Yu","year":"2023","journal-title":"Immunology"},{"key":"2026102212050919000_14.10.e015492.54","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0811413"},{"key":"2026102212050919000_14.10.e015492.55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012504","article-title":"Novel tetrameric bispecific KK-LC-1\u00d7CD16A-armed memory-like NK cells enhance antitumor efficacy in gastric cancer","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:05:23Z","timestamp":1792695923000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,22]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jitc-2026-015492"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015492","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}